Cargando…
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391138/ https://www.ncbi.nlm.nih.gov/pubmed/34057394 http://dx.doi.org/10.18553/jmcp.2021.27.6.797 |
| _version_ | 1785082635528175616 |
|---|---|
| author | Beinfeld, Molly Atlas, Steven J Touchette, Daniel McKenna, Avery Rind, David Pearson, Steven D |
| author_facet | Beinfeld, Molly Atlas, Steven J Touchette, Daniel McKenna, Avery Rind, David Pearson, Steven D |
| author_sort | Beinfeld, Molly |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10391138 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103911382023-08-02 The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council Beinfeld, Molly Atlas, Steven J Touchette, Daniel McKenna, Avery Rind, David Pearson, Steven D J Manag Care Spec Pharm Perspectives on Value Academy of Managed Care Pharmacy 2021-06 /pmc/articles/PMC10391138/ /pubmed/34057394 http://dx.doi.org/10.18553/jmcp.2021.27.6.797 Text en Copyright © 2021, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Perspectives on Value Beinfeld, Molly Atlas, Steven J Touchette, Daniel McKenna, Avery Rind, David Pearson, Steven D The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_fullStr | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_full_unstemmed | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_short | The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council |
| title_sort | effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for bcg-unresponsive non-muscle-invasive bladder cancer: a summary from the institute for clinical and economic review’s midwest comparative effectiveness public advisory council |
| topic | Perspectives on Value |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391138/ https://www.ncbi.nlm.nih.gov/pubmed/34057394 http://dx.doi.org/10.18553/jmcp.2021.27.6.797 |
| work_keys_str_mv | AT beinfeldmolly theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT atlasstevenj theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT touchettedaniel theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT mckennaavery theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT rinddavid theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend theeffectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT beinfeldmolly effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT atlasstevenj effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT touchettedaniel effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT mckennaavery effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT rinddavid effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil AT pearsonstevend effectivenessandvalueofnadofaragenefiradenovecoportuzumabmonatoxandpembrolizumabforbcgunresponsivenonmuscleinvasivebladdercancerasummaryfromtheinstituteforclinicalandeconomicreviewsmidwestcomparativeeffectivenesspublicadvisorycouncil |